Dr. Lal PathLabs to acquire 70% of SN Genelab

Dr. Lal PathLabs Limited (

) has approved the acquisition of a 70% stake in Gujarat-based SN Genelab for ₹168 crore. The transaction also includes a performance-linked earn-out capped at ₹31.5 crore. SN Genelab will become a subsidiary after completion, which is expected by November 30, 2026. Your view The acquisition expands Dr. Lal PathLabs' presence in Gujarat and adds another laboratory business to its network. The key factor is integration. I would watch the acquired business's revenue growth, margins, utilisation and contribution to the consolidated business after completion. The ₹31.5 crore earn-out also makes post-acquisition performance an important variable to track. Disclosure: I do not hold any position or have any interest in Dr. Lal PathLabs Limited as of the time of posting.